Angiex is a technology company.
Angiex has raised $27.0M across 2 funding rounds.
Angiex has raised $27.0M in total across 2 funding rounds.
Angiex has raised $27.0M in total across 2 funding rounds.
Angiex's investors include Gaingels, Khosla Ventures, MarsBio, Presight Capital, SOSV, Tuesday Capital.
Angiex is a biotechnology company developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) to target the hallmarks of cancer lethality, with a vision to make cancer a non-lethal disease.[1][2][3] Their lead product, AGX101, a TM4SF1-directed ND-ADC, treats solid tumors by delivering chemotherapeutic payloads directly to the nucleus of tumor cells and tumor vascular endothelial cells, addressing high mortality rates where over one-third of people in developed countries develop cancer and 10 million die annually.[1][2][3] The company serves oncology patients and the medical community, solving the problem of ineffective solid tumor therapies through selective nuclear delivery that minimizes damage to healthy tissue; AGX101 entered Phase 1 clinical trials in August 2024, with the first patient dosed.[1][2][3]
Headquartered in Cambridge, Massachusetts, Angiex has raised under $5 million in funding and employs fewer than 25 people, leveraging its location's biotech ecosystem for efficient growth toward clinical milestones and pipeline expansion.[1][5]
Angiex was founded by experts in tumor blood vessel biology who discovered VEGF-A, positioning them as leaders in the field.[2] The idea emerged from reviving TM4SF1—an old target from Bristol-Myers Squibb trials in 1986-1991—with modern ND-ADC technology to exploit its expression in proliferating endothelial cells and most tumor cells, enabling targeted delivery for cancer and vascular diseases.[3][4] CEO Paul Jaminet has highlighted Cambridge's incubation ecosystem, expertise, and capital as pivotal for early traction, allowing rapid advancement of TM4SF1-directed therapies.[5] Key early moments include preclinical efficacy data against human xenografts and mouse syngeneic tumors, leading to AGX101's progression to Phase 1 dosing in 2024.[1][3][4]
Angiex rides the ADC revolution in oncology, where antibody-drug conjugates have surged due to improved targeting and payloads, amid market forces like rising solid tumor incidence and demand for therapies with better margins over traditional chemo.[1][2][4] Timing is ideal post-2024 Phase 1 initiation for AGX101, capitalizing on TM4SF1's pan-cancer expression and historical validation, while nuclear delivery differentiates from surface-targeting ADCs.[3] In Cambridge's biotech hub, Angiex influences the ecosystem by out-licensing TM4SF1 antibodies for vascular indications and advancing internal cancer biotherapeutics, fostering innovation in tumor microenvironment targeting.[4][5]
Angiex's near-term focus is expanding AGX101's Phase 1 data readout, potentially unlocking partnerships given its ambition for high-quality collaborators and preclinical successes.[2][3] Broader trends like ADC payload diversification and AI-driven biology will shape its pipeline, with TM4SF1's versatility enabling cardiovascular expansions.[4] Influence may evolve from niche innovator to ecosystem leader if Phase 1 validates nuclear delivery's efficacy, reinforcing its mission to end cancer lethality and tying back to transforming a disease killing 10 million yearly into a manageable one.[1][2]
Angiex has raised $27.0M across 2 funding rounds. Most recently, it raised $25.0M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $25.0M Series B | Gaingels, Khosla Ventures, MarsBio, Presight Capital, SOSV, Tuesday Capital | |
| Oct 1, 2020 | $2.0M Venture Round | Gaingels, Khosla Ventures, MarsBio, Presight Capital, SOSV, Tuesday Capital |